早发性卵巢功能不全的临床诊疗进展

doi:10.12280/gjszjk.20200169

摘要/Abstract

摘要：

早发性卵巢功能不全（premature ovarian insufficiency,POI）是指女性40岁前卵巢功能衰退,严重影响育龄女性身心健康。大多数POI病因不明,目前发现的病因有遗传因素、免疫因素和医源性因素等。POI女性生育能力低下,仅依靠激素补充治疗（hormone replacement therapy,HRT）改善症状还远远不够,尤其在生育力保存方面尚无明确有效的治疗方法。近年来,辅助生殖技术为有生育需求的POI患者提供一定的治疗手段,卵巢组织冷冻移植、干细胞移植也是新兴的治疗方法。对POI的临床诊疗进展进行了综述。

关键词: 原发性卵巢功能不全, 生育力, 雌激素替代疗法, 生殖技术,辅助, 干细胞移植

Abstract:

Premature ovarian insufficiency (POI) is characterized by the decline of ovarian function before the age of 40 years, with severe influence on the physical and mental health of women of childbearing age. The etiology of most POIs remains unclear, which currently includes genetic factors, immunological factors and iatrogenic factors. POI patients have the reduced fertility. It is not enough to improve symptoms by hormone replacement therapy (HRT). However, there is no effective treatment so far, especially in terms of fertility preservation. In recent years, assisted reproductive technology has provided certain treatments for POI patients with fertility needs. In addition, the frozen ovarian tissue transplantation and stem cell transplantation may be the new options. This review will describe the progress of clinical diagnosis and treatment of POI.

Key words: Primary ovarian insufficiency, Fertility, Estrogen replacement therapy, Reproductive techniques,assisted, Stem cell transplantation

程铭, 贾婵维, 刘英. 早发性卵巢功能不全的临床诊疗进展[J]. 国际生殖健康/计划生育, 2021, 40(2): 137-141.

CHENG Ming, JIA Chan-wei, LIU Ying. Advances in Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(2): 137-141.

参考文献 31

[1]	Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea[J]. Fertil Steril, 2006,86(5 Suppl 1):S148-155. doi: 10.1016/j.fertnstert.2006.08.013. doi: 10.1016/j.fertnstert.2006.08.013 URL pmid: 17055812
[2]	Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency[J]. Hum Reprod, 2016,31(5):926-937. doi: 10.1093/humrep/dew027. doi: 10.1093/humrep/dew027 URL pmid: 27008889
[3]	Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women′s midlife health and menopause hormone therapy[J]. Climacteric, 2016,19(2):109-150. doi: 10.3109/13697137.2015.1129166. doi: 10.3109/13697137.2015.1129166 URL pmid: 26872610
[4]	陈子江, 田秦杰, 乔杰, 等. 早发性卵巢功能不全的临床诊疗中国专家共识[J]. 中华妇产科杂志, 2017,52(9):577-581. doi: 10.3760/cma.j.issn.0529-567x.2017.09.001.
[5]	Słopień R. Neurological health and premature ovarian insufficiency-pathogenesis and clinical management[J]. Prz Menopauzalny, 2018,17(3):120-123. doi: 10.5114/pm.2018.78555. doi: 10.5114/pm.2018.78555 URL pmid: 30356991
[6]	Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of ′poor response′ to ovarian stimulation for in vitro fertilization: the Bologna criteria[J]. Hum Reprod, 2011,26(7):1616-1624. doi: 10.1093/humrep/der092. doi: 10.1093/humrep/der092 URL
[7]	Jiao X, Zhang H, Ke H, et al. Premature Ovarian Insufficiency: Phenotypic Characterization Within Different Etiologies[J]. J Clin Endocrinol Metab, 2017,102(7):2281-2290. doi: 10.1210/jc.2016-3960. doi: 10.1210/jc.2016-3960 URL pmid: 28368522
[8]	Rossetti R, Ferrari I, Bonomi M, et al. Genetics of primary ovarian insufficiency[J]. Clin Genet, 2017,91(2):183-198. doi: 10.1111/cge.12921. doi: 10.1111/cge.12921 URL pmid: 27861765
[9]	Sanfins A, Rodrigues P, Albertini DF. GDF-9 and BMP-15 direct the follicle symphony[J]. J Assist Reprod Genet, 2018,35(10):1741-1750. doi: 10.1007/s10815-018-1268-4. doi: 10.1007/s10815-018-1268-4 URL pmid: 30039232
[10]	Venturella R, De Vivo V, Carlea A, et al. The Genetics of Non-Syndromic Primary Ovarian Insufficiency: A Systematic Review[J]. Int J Fertil Steril, 2019,13(3):161-168. doi: 10.22074/ijfs.2019.5599. doi: 10.22074/ijfs.2019.5599 URL pmid: 31310068
[11]	吴结英, 胡卫华. 卵巢早衰的病因学研究进展[J]. 国际生殖健康/计划生育杂志, 2019,38(4):332-336,344. doi: 10.3969/j.issn.1674-1889.2019.04.016.
[12]	Domniz N, Meirow D. Premature ovarian insufficiency and autoimmune diseases[J]. Best Pract Res Clin Obstet Gynaecol, 2019,60:42-55. doi: 10.1016/j.bpobgyn.2019.07.008. doi: 10.1016/j.bpobgyn.2019.07.008 URL pmid: 31495598
[13]	Hickman LC, Llarena NC, Valentine LN, et al. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists[J]. J Assist Reprod Genet, 2018,35(4):571-581. doi: 10.1007/s10815-018-1128-2. doi: 10.1007/s10815-018-1128-2 URL pmid: 29470701
[14]	Cosgrove CM, Salani R. Ovarian effects of radiation and cytotoxic chemotherapy damage[J]. Best Pract Res Clin Obstet Gynaecol, 2019,55:37-48. doi: 10.1016/j.bpobgyn.2018.07.008. doi: 10.1016/j.bpobgyn.2018.07.008 URL pmid: 30166215
[15]	Sweed MS, Makled AK, El-Sayed MA, et al. Ovarian Reserve Following Laparoscopic Ovarian Cystectomy vs Cyst Deroofing for Endometriomas[J]. J Minim Invasive Gynecol, 2019,26(5):877-882. doi: 10.1016/j.jmig.2018.06.022. doi: 10.1016/j.jmig.2018.06.022 URL pmid: 30193971
[16]	Ge W, Li L, Dyce PW, et al. Establishment and depletion of the ovarian reserve: physiology and impact of environmental chemicals[J]. Cell Mol Life Sci, 2019,76(9):1729-1746. doi: 10.1007/s00018-019-03028-1. doi: 10.1007/s00018-019-03028-1 URL pmid: 30810760
[17]	Calik-Ksepka A, Grymowicz M, Rudnicka E, et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency[J]. Prz Menopauzalny, 2018,17(3):131-134. doi: 10.5114/pm.2018.78558. doi: 10.5114/pm.2018.78558 URL pmid: 30357024
[18]	No authors listed. Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency[J]. Obstet Gynecol, 2017,129(5):e134-134e141. doi: 10.1097/AOG.0000000000002044. doi: 10.1097/AOG.0000000000002044 URL pmid: 28426619
[19]	Dragojevi Diki S, Vasiljevi M, Jovanovi A, et al. Premature ovarian insufficiency-novel hormonal approaches in optimizing fertility[J]. Gynecol Endocrinol, 2020,36(2):162-165. doi: 10.1080/09513590.2019.1640203. doi: 10.1080/09513590.2019.1640203 URL pmid: 31311350
[20]	Wong Q, Yeung T, Yung S, et al. The effect of 12-month dehydroepiandrosterone supplementation on the menstrual pattern, ovarian reserve markers, and safety profile in women with premature ovarian insufficiency[J]. J Assist Reprod Genet, 2018,35(5):857-862. doi: 10.1007/s10815-018-1152-2. doi: 10.1007/s10815-018-1152-2 URL pmid: 29520734
[21]	Biglia N, Bounous VE, De Seta F, et al. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update[J]. Ecancermedicalscience, 2019,13:909. doi: 10.3332/ecancer.2019.909. doi: 10.3332/ecancer.2019.909 URL pmid: 31123492
[22]	Petríková J, Lazúrová I. Ovarian failure and polycystic ovary syndrome[J]. Autoimmun Rev, 2012,11(6/7):A471-478. doi: 10.1016/j.autrev.2011.11.010. doi: 10.1016/j.autrev.2011.11.010 URL
[23]	Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency[J]. Lancet, 2014,383(9935):2152-2167. doi: 10.1016/S0140-6736(13)61684-0. doi: 10.1016/S0140-6736(13)61684-0 URL
[24]	Fraison E, Crawford G, Casper G, et al. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review[J]. Reprod Biomed Online, 2019,39(3):467-476. doi: 10.1016/j.rbmo.2019.04.019. doi: 10.1016/j.rbmo.2019.04.019 URL pmid: 31279714
[25]	Kawashima I, Kawamura K. Regulation of follicle growth through hormonal factors and mechanical cues mediated by Hippo signaling pathway[J]. Syst Biol Reprod Med, 2018,64(1):3-11. doi: 10.1080/19396368.2017.1411990. doi: 10.1080/19396368.2017.1411990 URL pmid: 29224376
[26]	Lin J, Li XL, Song H, et al. A general description for Chinese medicine in treating premature ovarian failure[J]. Chin J Integr Med, 2017,23(2):91-97. doi: 10.1007/s11655-016-2642-7. doi: 10.1007/s11655-016-2642-7 URL pmid: 28265850
[27]	Álvarez-Viejo M. Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective[J]. World J Stem Cells, 2020,12(2):100-109. doi: 10.4252/wjsc.v12.i2.100. doi: 10.4252/wjsc.v12.i2.100 URL pmid: 32184935
[28]	Sheikhansari G, Aghebati-Maleki L, Nouri M, et al. Current approaches for the treatment of premature ovarian failure with stem cell therapy[J]. Biomed Pharmacother, 2018,102:254-262. doi: 10.1016/j.biopha.2018.03.056. doi: 10.1016/j.biopha.2018.03.056 URL pmid: 29567538
[29]	Fazeli Z, Abedindo A, Omrani MD, et al. Mesenchymal Stem Cells (MSCs) Therapy for Recovery of Fertility: a Systematic Review[J]. Stem Cell Rev Rep, 2018,14(1):1-12. doi: 10.1007/s12015-017-9765-x. doi: 10.1007/s12015-017-9765-x URL pmid: 28884412
[30]	Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism[J]. Stem Cell Res Ther, 2019,10(1):46. doi: 10.1186/s13287-019-1136-x. doi: 10.1186/s13287-019-1136-x URL pmid: 30683144
[31]	Ahmadian S, Mahdipour M, Pazhang M, et al. Effectiveness of Stem Cell Therapy in the Treatment of Ovarian Disorders and Female Infertility: A Systematic Review[J]. Curr Stem Cell Res Ther, 2020,15(2):173-186. doi: 10.2174/1574888X14666191119122159. doi: 10.2174/1574888X14666191119122159 URL pmid: 31746298